High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

December 6, 2018

Study Completion Date

December 6, 2018

Conditions
Lymphoma
Interventions
DRUG

Gemcitabine

2775 mg/m2 by vein over about 3 hours on days -8 and -3.

DRUG

Busulfan

"32 mg/m2 test dose with PKs as outpatient and on day -10 as inpatient~AUC 4,000 by vein over about 3 hours on days -8 to -5."

DRUG

Melphalan

60 mg/m2 by vein over about 30 minutes on days -3 and -2.

PROCEDURE

Stem Cell Transplantation

Infusion of stem cells on Day 0.

DRUG

Palifermin

60 mg/kg by vein over 30 seconds daily, Days -12 to -10 and Days 0 to 2.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT01200329 - High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease | Biotech Hunter | Biotech Hunter